ATNX - Athenex, Inc.
| Previous Close | 17.99 |
| Open | 18.00 |
| Bid | 17.99 x 1100 |
| Ask | 17.99 x 800 |
| Day's Range | 17.84 - 18.18 |
| 52 Week Range | 9.38 - 20.90 |
| Volume | 467,037 |
| Avg. Volume | 463,343 |
| Market Cap | 1.387B |
| Beta (3Y Monthly) | -0.94 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire•14 days ago
Athenex and PharmaEssentia Announce Positive Early Signals of Clinical Activity of KX2-391 (INN: tirbanibulin) in Patients with Psoriasis
BUFFALO, N.Y. and TAIPEI, Taiwan, June 06, 2019 -- Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and.
- GlobeNewswire•14 days ago
Athenex Provides an Update on its Chongqing API Plant
Athenex, Inc. (ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer, today announced that its active pharmaceutical ingredient (API) plant in Chongqing, China has voluntarily suspended production activities. The voluntary temporary suspension occurred last month, and the Company expects to have a resolution by the end of the third quarter of 2019, subject to inspection and evaluation by the Department of Emergency Management of Chongqing.
- GlobeNewswire•21 days ago
Athenex to Present at the 2019 ASCO Annual Meeting
BUFFALO, N.Y., May 30, 2019 -- Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies.
- GlobeNewswire•last month
Athenex Announces $100 Million Private Placement
Athenex, Inc. (ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that it has directly entered into an agreement for the sale of its common stock in a private placement with three institutional investors, namely Perceptive Advisors, Avoro Capital Advisors (formerly known as venBio Select Advisor) and OrbiMed. The transaction is expected to result in gross proceeds to Athenex of approximately $100 million, before deducting offering expenses.
- GlobeNewswire•2 months ago
Athenex Announces Promising Early and Complete Response Data from a Clinical Study of Oraxol in Cutaneous Angiosarcoma
BUFFALO, N.Y., May 03, 2019 -- Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies.
- GlobeNewswire•2 months ago
Athenex, Inc. to Report First Quarter 2019 Earnings Results on May 9, 2019
BUFFALO, N.Y., April 25, 2019 -- Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel.
- GlobeNewswire•2 months ago
Athenex Announces Abstracts Accepted for Presentation at the 2019 American Society of Clinical Oncology Annual Meeting
BUFFALO, N.Y., April 23, 2019 -- Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel.
- GlobeNewswire•3 months ago
Athenex Announces Appointment of John Koh as a New Board Member
Athenex, Inc. (ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced the appointment of John Koh as a Director on Athenex’s Board, effective April 1, 2019. Mr. Koh joins the Company’s expanded Board of Directors together with recently announced additions of Dr. John Vierling, Ms. Stephanie Davis and Mr. Jordan Kanfer.
- GlobeNewswire•3 months ago
Athenex Announces Appointment of Jordan S. Kanfer to Board of Directors
Athenex, Inc. (ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced the appointment of Jordan S. Kanfer, Managing Director, Convertible and Equity Research at Opti Capital Management, to its Board of Directors, effective April 1, 2019. Mr. Kanfer will replace SongYi Zhang, J.D., who is stepping down.
- GlobeNewswire•3 months ago
Athenex Announces Appointment of Dr. Daniel Von Hoff as Chairman of the Scientific Advisory Board of Axis Therapeutics Limited
BUFFALO, N.Y., March 28, 2019 -- Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel.
- GlobeNewswire•3 months ago
New Research Coverage Highlights UnitedHealth Group, Ultragenyx Pharmaceutical, Navistar International, REGENXBIO, Par Pacific, and Athenex — Consolidated Revenues, Company Growth, and Expectations for 2019
NEW YORK, March 26, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- GlobeNewswire•3 months ago
Athenex Announces Xiangxue Life Sciences Receives IND Allowance from China’s National Medical Products Administration for Cancer Immunotherapy Drug Candidate
This company-sponsored IND allows Xiangxue Life Sciences (XLifeSc) to proceed to the next stage of clinical studies in China Encouraging positive clinical safety and efficacy.
- GlobeNewswire•3 months ago
Athenex Announces Expansion of Board of Directors
Athenex, Inc. (ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced the resignation of Sheldon Trainor-De Girolamo as a Director of the company. The company also announces the appointment of two new Directors: John Moore Vierling, MD, FACP, FAASLD, AGAF, tenured Professor of Medicine and Surgery at the Baylor College of Medicine, and Stephanie Davis, Senior Client Partner at Korn Ferry.
- GlobeNewswire•3 months ago
SunGen Pharma and Athenex Pharmaceutical Division Announce Busulfan Injection Product Launch
PRINCETON, N.J., March 13, 2019 -- SunGen Pharma, a privately held specialty pharmaceutical company which develops, contract manufactures, and sells pharmaceutical finished.
- GlobeNewswire•3 months ago
Athenex, Inc. Announces Fourth Quarter and Year Ended December 31, 2018 Financial Results and Provides Corporate Update
Oraxol Phase III clinical trial in metastatic breast cancer fully enrolled Positive Phase III topline results of KX2-391 in actinic keratosis featured in late breaker session.
- GlobeNewswire•3 months ago
Athenex to Present Preclinical Data of Oraxol in the Treatment of Angiosarcoma at the American Association for Cancer Research Annual Meeting 2019
BUFFALO, N.Y., March 08, 2019 -- Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel.
- GlobeNewswire•3 months ago
Athenex Regains Rights to KX2-391 in China
BUFFALO, N.Y., March 07, 2019 -- Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel.
- PR Newswire•4 months ago
Almirall and Athenex Announce Positive Topline Results from Two Phase III Studies of KX2-391 Ointment 1% Featured in Late Breaker Program at the 2019 American Academy of Dermatology Annual Meeting
- Results show that 44% and 54% of patients in studies KX01-AK-003 and KX01-AK-004, respectively, achieved 100% AK lesion clearance at Day 57. - Safety profile of KX2-391 ointment may be an important competitive ...
- GlobeNewswire•4 months ago
Athenex Announces Positive Topline Results from Two Phase III Studies of KX2-391 Ointment 1% Featured in Late Breaker Program at the 2019 American Academy of Dermatology Annual Meeting
Results show that 44% and 54% of patients in studies KX01-AK-003 and KX01-AK-004, respectively, achieved 100% AK lesion clearance at Day 57 Safety profile of KX2-391 ointment.
- GlobeNewswire•4 months ago
New Research Coverage Highlights The Wendy's, Rite Aid, Invesco, LendingClub, Diodes, and Athenex — Consolidated Revenues, Company Growth, and Expectations for 2019
NEW YORK, Feb. 25, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- GlobeNewswire•4 months ago
Athenex to Host Conference Call with Key Opinion Leader Following Oral Presentation of Phase III Results of KX2-391 Ointment in the Treatment of Actinic Keratosis at the American Academy of Dermatology Annual Meeting
BUFFALO, N.Y., Feb. 25, 2019 -- Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel.
- GlobeNewswire•4 months ago
Athenex, Inc. to Report Fourth Quarter and Fiscal Year 2018 Earnings Results on March 11, 2019
BUFFALO, N.Y., Feb. 14, 2019 -- Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel.
- GlobeNewswire•4 months ago
Athenex Announces Late-Breaking Oral Presentation of KX2-391 Ointment in Two Phase III Studies at the American Academy of Dermatology Annual Meeting
BUFFALO, N.Y., Feb. 04, 2019 -- Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel.
- GlobeNewswire•5 months ago
Athenex Announces Completion of Target Enrollment in the Oraxol Phase III Study
BUFFALO, N.Y., Jan. 09, 2019 -- Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel.
- GlobeNewswire•6 months ago
Chongqing Jingdong Pharmaceutical and Athenex Announce a Strategic Partnership and Licensing Agreement to Develop and Commercialize KX2-391 in China
Athenex, Inc. (ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that, through its subsidiary, it has entered into a licensing and partnership agreement with Chongqing Jingdong Junzhuo Pharmaceutical Co., Ltd. (“Chongqing Jingdong Pharmaceutical”) on December 30, 2018 to exclusively develop and commercialize KX2-391 for the treatment of actinic keratosis and oncology indications in humans in China. KX2-391, also known as KX-01, is a first-in-class dual Src kinase and tubulin polymerization inhibitor.